EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery and Activity Evaluation of Novel Dibenzoxazepinone Derivatives as Glycogen Phosphorylase Inhibitors

Dongrui Liu, Zhiwei Yan, Youde Wang iD, Shuai Li, Yachun Guo, Tienan Wang, Jinjia Guo, Liying Zhang

Molecules · 2025

DOI: 10.3390/molecules30244797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Dongrui Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Traditional Chinese Medicine Research and Development of Hebei Province, Institute of Traditional Chinese Medicine, Chengde Medical Uni…. Hauptthemen laut MEDLINE: Glycogen Phosphorylase, Enzyme Inhibitors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province under, Natural Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of glycogen phosphorylases (GP) has been regarded as a therapeutic strategy for blood glucose control in diabetes. In this study, a series of novel dibenzoxazepinone derivatives was synthesized. The in vitro activity screening results indicated that compound Id most significantly inhibited glycogen phosphorylase (GP) activity, with an IC50 of 266 ± 1 nM, which was superior to the positive control drug PSN-357, a Phase II clinical GP inhibitor from Japan’s OSI Corporation. In vivo experiments showed that Id could significantly reduce blood glucose levels in adrenaline-induced acute hyperglycemic mice and high-fat-diet-induced obese and diabetic (DIO) mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen PhosphorylaseEnzyme InhibitorsAnimalsMiceDrug DiscoveryBlood GlucoseDiet, High-FatStructure-Activity RelationshipMaleMolecular StructureHyperglycemiaObesityHypoglycemic AgentsHumans

Stichwörter der Autor:innen

diabetesdibenzoxazepinone derivativesglycogen phosphorylase inhibitorsglycogenolysishypoglycemic

Substanzen

Glycogen PhosphorylaseEnzyme InhibitorsBlood GlucoseHypoglycemic Agents

Autor:innen und Institutionen

  • Laboratory of Traditional Chinese Medicine Research and Development of Hebei Province, Institute of Traditional Chinese Medicine, Chengde Medical University, Chengde 067000, China.
  • Department of Pathogen Biology, Chengde Medical University, Chengde 067000, China.
  • Jingfukang Pharmaceutical Group Co., Ltd., Chengde 067000, China.

ORCID-Profile: Youde Wang

Förderung

  • Natural Science Foundation of Hebei Province under
  • Natural Science Foundation of Hebei Province

Zitieren

APA

Liu, D., Yan, Z., Wang, Y., Li, S., Guo, Y., Wang, T., Guo, J., & Zhang, L. (2025). Discovery and Activity Evaluation of Novel Dibenzoxazepinone Derivatives as Glycogen Phosphorylase Inhibitors. Molecules. https://doi.org/10.3390/molecules30244797

Vancouver

Liu D, Yan Z, Wang Y, Li S, Guo Y, Wang T, et al. Discovery and Activity Evaluation of Novel Dibenzoxazepinone Derivatives as Glycogen Phosphorylase Inhibitors. Molecules. 2025. doi:10.3390/molecules30244797

BibTeX
@article{Liu2025,
  author = {Liu, Dongrui and Yan, Zhiwei and Wang, Youde and Li, Shuai and Guo, Yachun and Wang, Tienan and Guo, Jinjia and Zhang, Liying},
  title = {Discovery and Activity Evaluation of Novel Dibenzoxazepinone Derivatives as Glycogen Phosphorylase Inhibitors},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30244797}
}
Kostenlos starten →